Drugs / TAS2940
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04982926 | Sep 2021 → Feb 2025 | breast cancer, glioblastoma, non-small cell lung carcinoma | Taiho Oncology, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS2940 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04982926 ↗ |
| Action | Inhibit | “TAS2940 is a small molecule inhibitor of ERBB family proteins HER2 and EGFR.” NCT04982926 ↗ |
| Modality | Small molecule | “TAS2940 is a small molecule inhibitor of ERBB family proteins HER2 and EGFR.” NCT04982926 ↗ |
| Route | Oral | “TAS2940 administered orally.” NCT04982926 ↗ |
| Target | EGFR | “TAS2940 is a small molecule inhibitor of ERBB family proteins HER2 and EGFR.” NCT04982926 ↗ |